BioSpace News Archive

Retinitis pigmentosa (RP) is a group of rare, genetic disorders that involve breakdown and loss of cells in the retina, which is the light sensitive tissue that lines the back of the eye.

From site selection in Guangzhou Biopark to handover during the global pandemic, 17,000-square meter site was completed in less than two years

NeoDynamics AB, a MedTech company dedicated to advancing diagnosis and care of breast cancer, announces that the European Patent Office has issued a Communication under Rule 71 EPC and intends to grant a European patent for NeoDynamics pulse biopsy tools, including a multi-purpose driver supporting several different needle options.

ONK Therapeutics Ltd, an innovative natural killer cell therapy company, announced that it has appointed Hugh O’Dowd as Director and independent Non-executive Chairman of its Board of Directors.

Founding investor Forbion joined by co-lead investors, Morningside Ventures and Ascendant BioCapital, and other leaders in global biopharmaceutical investment

HEXO Corp. (“HEXO”, or the “Company”) (TSX: HEXO; NYSE: HEXO) is pleased to announce the appointment of Rose Marie Gage to its Board of Directors

Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today certain unaudited preliminary fourth quarter and full-year 2020 revenue results. Preliminary Fourth Quarter and Full-Year 2020 Revenue Results Fourth quarter 2020 revenue is expected to be in a range of $387 to $389 million, representing a decrease of 2.1% to 1.6% on a reported basis and a decrease of 1.9% to 1.4% on an

Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today reported preliminary unaudited revenue results for the three months ended December 31, 2020 and introduced revenue guidance expectations for the twelve months ended December 31, 2021. Management Commentary: “We continued to see improvements in the operating environment in our key markets in the fourth quarter as evidenced by

The board of directors of Eli Lilly and Company (NYSE: LLY) has elected Gabrielle Sulzberger as a new member, effective January 25, 2021 . As a member of Lilly’s board, she will serve on both the Audit Committee and the Ethics and Compliance Committee. Ms. Sulzberger is a strategic advisor to Two Sigma Impact, a private equity

The continued progression of Microbot Medical Inc.’s (Nasdaq: MBOT) LIBERTY™ Robotic System was further demonstrated as the Company announced the successful completion of an additional feasibility animal study using the world’s first fully disposable surgical robotic system